A New Augmentation Strategy Against Depression Combining SSRIs and the N-terminal Fragment of Galanin (1-15)

Overview

Journal Curr Neuropharmacol

Publisher Bentham Science Publishers

Date 2024 Nov 1

PMID 39484753

Authors

Antonio Flores-Burgess

Carmelo Millon

Noelia Cantero-Garcia

Juan Pedro Pineda-Gomez

Marta Flores-Gomez

Zaida Diaz-Cabiale

Affiliations

Soon will be listed here.

Abstract

Depression is one of the most disabling mental disorders, with the second highest social burden; its prevalence has grown by more than 27% in recent years, affecting 246 million in 2021. Despite the wide range of antidepressants available, more than 50% of patients show treatment-resistant depression. In this review, we summarized the progress in developing a new augmentation strategy based on combining the N-terminal fragment of Galanin (1-15) and SSRI-type antidepressants in animal models.

References

Chisholm D, Sweeny K, Sheehan P, Rasmussen B, Smit F, Cuijpers P . Scaling-up treatment of depression and anxiety: a global return on investment analysis. Lancet Psychiatry. 2016; 3(5):415-24. DOI: 10.1016/S2215-0366(16)30024-4. View

. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet. 2021; 398(10312):1700-1712. PMC: 8500697. DOI: 10.1016/S0140-6736(21)02143-7. View

Hankin B, Abramson L . Development of gender differences in depression: description and possible explanations. Ann Med. 2000; 31(6):372-9. DOI: 10.3109/07853899908998794. View

Kessler R . Epidemiology of women and depression. J Affect Disord. 2003; 74(1):5-13. DOI: 10.1016/s0165-0327(02)00426-3. View

Lai H, Cleary M, Sitharthan T, Hunt G . Prevalence of comorbid substance use, anxiety and mood disorders in epidemiological surveys, 1990-2014: A systematic review and meta-analysis. Drug Alcohol Depend. 2015; 154:1-13. DOI: 10.1016/j.drugalcdep.2015.05.031. View

Hoffmann A, Sportelli V, Ziller M, Spengler D . Epigenomics of Major Depressive Disorders and Schizophrenia: Early Life Decides. Int J Mol Sci. 2017; 18(8). PMC: 5578101. DOI: 10.3390/ijms18081711. View

Dean J, Keshavan M . The neurobiology of depression: An integrated view. Asian J Psychiatr. 2017; 27:101-111. DOI: 10.1016/j.ajp.2017.01.025. View

Malhi G, Mann J . Depression. Lancet. 2018; 392(10161):2299-2312. DOI: 10.1016/S0140-6736(18)31948-2. View

Jesulola E, Micalos P, Baguley I . Understanding the pathophysiology of depression: From monoamines to the neurogenesis hypothesis model - are we there yet?. Behav Brain Res. 2017; 341:79-90. DOI: 10.1016/j.bbr.2017.12.025. View

10.

Krishnan V, Nestler E . The molecular neurobiology of depression. Nature. 2008; 455(7215):894-902. PMC: 2721780. DOI: 10.1038/nature07455. View

11.

Mikulska J, Juszczyk G, Gawronska-Grzywacz M, Herbet M . HPA Axis in the Pathomechanism of Depression and Schizophrenia: New Therapeutic Strategies Based on Its Participation. Brain Sci. 2021; 11(10). PMC: 8533829. DOI: 10.3390/brainsci11101298. View

12.

Boku S, Nakagawa S, Toda H, Hishimoto A . Neural basis of major depressive disorder: Beyond monoamine hypothesis. Psychiatry Clin Neurosci. 2017; 72(1):3-12. DOI: 10.1111/pcn.12604. View

13.

de Kloet E, Joels M, Holsboer F . Stress and the brain: from adaptation to disease. Nat Rev Neurosci. 2005; 6(6):463-75. DOI: 10.1038/nrn1683. View

14.

Tartt A, Mariani M, Hen R, Mann J, Boldrini M . Dysregulation of adult hippocampal neuroplasticity in major depression: pathogenesis and therapeutic implications. Mol Psychiatry. 2022; 27(6):2689-2699. PMC: 9167750. DOI: 10.1038/s41380-022-01520-y. View

15.

Flores-Burgess A, Millon C, Gago B, Garcia-Duran L, Cantero-Garcia N, Puigcerver A . Galanin (1-15) Enhances the Behavioral Effects of Fluoxetine in the Olfactory Bulbectomy Rat, Suggesting a New Augmentation Strategy in Depression. Int J Neuropsychopharmacol. 2021; 25(4):307-318. PMC: 9017770. DOI: 10.1093/ijnp/pyab089. View

15.

Beurel E, Toups M, Nemeroff C . The Bidirectional Relationship of Depression and Inflammation: Double Trouble. Neuron. 2020; 107(2):234-256. PMC: 7381373. DOI: 10.1016/j.neuron.2020.06.002. View

16.

Duman R, Sanacora G, Krystal J . Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments. Neuron. 2019; 102(1):75-90. PMC: 6450409. DOI: 10.1016/j.neuron.2019.03.013. View

17.

Rana T, Behl T, Sehgal A, Singh S, Sharma N, Abdeen A . Exploring the role of neuropeptides in depression and anxiety. Prog Neuropsychopharmacol Biol Psychiatry. 2021; 114:110478. DOI: 10.1016/j.pnpbp.2021.110478. View

18.

Kormos V, Gaszner B . Role of neuropeptides in anxiety, stress, and depression: from animals to humans. Neuropeptides. 2013; 47(6):401-19. DOI: 10.1016/j.npep.2013.10.014. View

19.

Mandrioli R, Protti M, Mercolini L . New-Generation, Non-SSRI Antidepressants: Therapeutic Drug Monitoring and Pharmacological Interactions. Part 1: SNRIs, SMSs, SARIs. Curr Med Chem. 2017; 25(7):772-792. DOI: 10.2174/0929867324666170712165042. View